Navigation Links
Reglan Adverse Events More Than Doubled from 2006 to 2008
Date:7/7/2009

Recent data from the Food and Drug Administration’s Adverse Event Reporting System reveals that new cases of tardive dyskinesia or other movement disorders reported by users of Reglan (or its generic version, metoclopramide) more than doubled between 2006 and 2008. In February 2009, the FDA forced the manufacturers of Reglan and metoclopramide to add a black-box warning to their labels about the strong connection between tardive dyskinesia and the long-term use of Reglan.

Austin, Texas (Vocus) July 7, 2009 -- Recent data from the Food and Drug Administration’s Adverse Event Reporting System reveals that new cases of tardive dyskinesia or other movement disorders reported by users of Reglan (or its generic version, metoclopramide) more than doubled between 2006 and 2008, according to an analysis by Hissey Kientz, LLP. This represents a substantial increase in new adverse events related to Reglan.

“Another very striking aspect of this increase in Reglan-related side effects cases is that these were reported to the FDA before manufacturers were even requested to add a ‘black-box’ warning to the drugs’ labels,” says Shamus B. Mulderig, an attorney with Hissey Kientz, LLP. “As the agency begins to release data collected after this February’s warning notice was issued, and more patients and physicians become aware of the life-altering side effects of these drugs, the number of new cases reported to the FDA will undoubtedly continue to rise.”

Reglan and metoclopramide were approved by the FDA only for short-term treatment of certain gastrointestinal conditions, such as gastroesophageal reflux disease or diabetic gastroparesis. However, the manufacturers of these drugs derive substantial profit from their long-term use. The drugs work by speeding up the movement of the stomach muscles, which helps to increase the rate at which food moves from the stomach to the intestines.

In February 2009, the FDA forced the manufacturers of Reglan and metoclopramide to add a black-box warning to their labels about the strong connection between tardive dyskinesia and the long-term use of Reglan.

Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive movements of the extremities, including lip smacking, grimacing, tongue protrusion, rapid eye movements or blinking, puckering and pursing of the lips, or impaired movement of the fingers. Because the risk of tardive dyskinesia may be greatest in patients who have taken Reglan or metoclopramide for an extended period, the FDA required a “black box” warning which states that no one should use the drugs for longer than three months.

“Tardive dyskinesia is a debilitating disease which substantially alters the quality of one’s life. It may affect thousands who used Reglan or metoclopramide,” Mulderig says. “Tardive dyskinesia is a horrible affliction, is not reversible and has no cure. And because the FDA’s Adverse Event Reporting System is a voluntary reporting system, the number of reports received so far may seriously understate how widespread this affliction may be.”

Reglan is also linked to a serious and potentially fatal syndrome known as Neuroleptic Malignant Syndrome (NMS), according to articles published in the Archives of Internal Medicine and other medical journals. Symptoms of NMS include hyperthermia, muscle rigidity, altered consciousness, irregular pulse, blood pressure or heartbeat or other symptoms.

“In addition to requiring the manufacturers to place a black box warning on the labels of Reglan and metoclopramide, the FDA is demanding these companies conduct a risk evaluation and mitigation strategy to ensure that patients are provided with a medication guide that discusses the risks associated with these drugs,” says Mulderig. “Unfortunately, these measures taken by the understaffed and underfunded FDA come much too late for the individuals who have already developed tardive dyskinesia or NMS from the long-term use of Reglan.”

About Hissey Kientz, LLP
Hissey Kientz, LLP (http://www.hkllp.com/) is currently accepting cases involving individuals who may have developed tardive dyskinesia after using Reglan, as well as those affected by mesothelioma, asbestosis or lung cancer as a result of asbestos exposure; the Ortho Evra patch; digoxin toxicity from Digitek; primary pulmonary hypertension caused by Fen-Phen or “herbal Fen Phen;” the Composix Kugel mesh hernia patch; renal failure caused by Trasylol; the Duragesic or fentanyl pain patch; Raptiva; FELA railroad injuries; gadolinium MRI contrast dyes or other defective drugs and devices. To learn more about the firm and other drug cases, visit Hissey Kientz, LLP or call toll-free at (866) 275-4454.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2605904.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Analysis of FDA Adverse Events Data Reveals at Least 106 Serious Conditions Reported Among Reglan Users
2. Abbotts XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, Real World Patients in SPIRIT V Study
3. Waiting for biopsy results may adversely affect health
4. Womans Hospital Selects rL Solutions for Improved Adverse Event and Patient Safety Reporting
5. Tailored Drug Delivery Reduces Adverse Effects After PCI
6. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
7. Post-marketing studies finding adverse events in drugs used in children
8. Weight Watchers Receives Adverse U.K. VAT Ruling
9. Drugs With Marijuana Compounds Dont Boost Adverse Events
10. Large Study Identifies Most Costly Adverse Events in Childrens Hospitals
11. Large study identifies most costly adverse events in childrens hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Reglan Adverse Events More Than Doubled from 2006 to 2008
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology: